N/A N=10 Transcranial Direct Current Stimulation (tDCS)
Brain Fog
Primary: Perceived Ease of Use After 4 Weeks of Daily tDCS Use (TAM Score) — 30.5 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 The Efficient Brain Study
Metabolism - Cerebral Energy
Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude
N/A N=98 Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
Phase 4 N=26 Impact of Astaxanthin on Cognition in Recreationally Active Females
Mental Fatigue
Primary: Reaction Time — 402.7; 400; 426.4; 406.6 milliseconds
N/A N=27 Carbon Dioxide (CO2) and Cognitive Impairment
Healthy
Primary: Change in PMN (Polymorphonuclear Leukocyte) Activation as Measured by Basal Oxygen Consumption (OCR) — 18.74; 19.54 pmol/min
N/A N=40 Preventing Cognitive Decline
Cognitive Decline
Primary: Percentage of Trials Correct On Working Memory Test — 87.69; 91.57; 88.01; 91.68 percentage of correct trials — p=>0.05
Phase 3 N=226 EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
Breast Cancer · Neurotoxicity
Primary: The Level of Cognitive Dysfunction as Measured by the High Sensitivity Cognitive Screen (HSCS) Overall Score. — 12.2; 12.6; 3.9; 2.6 units on a scale*months — p=0.84
Phase 2 N=52 NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Cognitive Scores at Baseline and Week 12 — 96; 99; 101; 103 score on a scale
N/A N=12 Brain Stimulation and Cognitive Training
Bipolar Disorder · Schizo Affective Disorder · Schizophrenia
Primary: Participant Retention in Combination Treatment — 4; 5 Participants
N/A N=69 Exercise and Cognitive Retraining to Improve Cognition in Heart Failure.
Heart Failure
Primary: Verbal Memory Score Change — -0.08; -0.08; 0.18; -0.47 score on a scale
N/A N=26 Brain Stimulation and Enhancing Cognition in Older Adults
Cognitive Impairment, Mild · Depressive Symptoms · Anxiety
Primary: Cognitive and Memory Function — 56.5; 49.8 score on a scale
N/A N=42 Patient Centered-Rehabilitation ver111090.1
Cognitive Change
Primary: Object Location Touchscreen Task (Version C) Free Recall Total Error — 121.498; 99.77 centimeters — p=.300
N/A N=20 Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity
Obesity
Primary: Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) — .0468; .0492…
N/A N=180 MINDSpeed Food and Brain Training RCT
Low Education · Cognition · Cognitive Training
Primary: Executive Cognitive Function Composite Score — 0.211; 0.100; 0.142; 0.196 units on a scale
N/A N=33 Time Restricted Eating for Metabolic and Psychological Optimization
Mild Cognitive Impairment · Obesity
Primary: Change in Memory Composite Rank — 6.22 rank — p=<0.001
N/A N=165 Brain Health Together: A Live-Streaming Group-Based Digital Program
Mild Cognitive Impairment · Cognitive Decline · Cognitive Deterioration
Primary: Creyos Cognitive Composite - 3 Month — 0.27; 0.13 Change on z-score — p=0.346
Phase 4 N=30 Study to Assess the Efficacy of Cognitex
Elderly · Memory Impairment
Primary: Improvement of Cognitive Performance (Change From Baseline in Neuropsychological Computerized Test) — 3.46; 13.19; 7.92; 9.19 Points on a scale
N/A N=18 Brain Markers of Improvements in Cognitive Functioning
TBI (Traumatic Brain Injury) · Brain Injuries · Stress
Primary: Composite Score of Attention and Executive Functioning From a Neurocognitive Test Battery — 0.18; -0.06 units on a scale
Phase 4 N=61 Neurocognitive Benefits of a Weight Management Program
Overweight and Obesity
Primary: Blood Oxygen Level-dependent (BOLD) Response to High-calorie Foods Cues Minus Neutral Objects in Left Anterior Cingulate Cortex — -0.05; -0.16 percent BOLD signal change
N/A N=22 Brain and Cognitive Changes After Reasoning Training in Individuals With Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Change From Baseline in California Verbal Learning Task Score — 3.04; 5.17; 4.22; 7.04 score on a scale
Phase 2 N=91 Cognitive Enhancement Through Transcranial Laser Therapy
Healthy Participants · Mild Cognitive Impairment
Primary: Psychomotor Vigilance Task (PVT) — 341.89; 344.09; 331.11; 330.75 msec — p=0.79
N/A N=90 Mindfulness, Mental Fatigue, Inhibitory Control and Endurance Performance in Athletes
Mental Fatigue
Primary: Inhibitory Control: Reaction Time — 461.01; 448.68; 444.35; 465.88 millisecond
Phase 2 N=30 Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome
Organic Brain Syndrome, Nonpsychotic · Neurocognitive Disorders · Mental Disorder, Organic
Primary: The Number of Patients With Severe Adverse Events and Adverse Reactions — 0 Participants
N/A N=81 Memory and Fear Study (Fear of Memory Loss Study)
Anxiety and Fear
Primary: Fear and Avoidance of Memory Loss (FAM) Scale Score at Follow-up — 63.9; 60.3 score on a scale
Phase 2 N=113 Nutraceutical Effects on Long-Term Memory
Aging
Primary: Delay Eyeblink Conditioning — 52.32; 56.88 percentage of conditioned responses
N/A N=62 Heart Rate and Breathing Effects on Attention and Memory
Aging · Alzheimer Disease · Age-related Cognitive Decline
Primary: Change in Plasma Amyloid Beta (Aβ) Levels — 0.343; -0.371; 0.381; -0.332 Z-score — p=0.817
Phase 4 N=72 Effects of a Common Cold Treatment on Cognitive Function
Common Cold
Primary: Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test — 4.8; 1.3 Valid responses — p=0.0008
Phase 4 N=28 Mild Cognitive Impairment in Parkinson's Disease
Parkinson's Disease · Mild Cognitive Impairment
Primary: Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC) — 3.92; 3.48 scores on the CGIC
N/A N=53 Mindfulness Training, Mental Fatigue, Endurance Performance and Neurocognitive Functions
Mindfulness Training · Neurocognitive Function · Sports Performance
Primary: Inhibitory Control: Reaction Time — 10.79; 5.47; 4.11; -0.61 millisecond — p=> 0.05
N/A N=49 Cognitive Dysfunction in Parkinson's Disease
Parkinson's Disease
Primary: Change in Magnetoencephalography (MEG) Connectivity Measures